Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

LGND vs OKUR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

LGND Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 9–1 Matrix Metrics)

LGND Overall Winner 6-Pillar Tally: LGND 6 – 0 OKUR Matrix Metrics: LGND 9 – 1 OKUR

As of Nov 20, 2026, Ligand Pharmaceuticals Inc. (LGND) is the stronger overall head-to-head candidate over OnKure Therapeutics, Inc. (OKUR) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). LGND carries a Unified Composite Score of 46.5/100 (HOLD) at $286.85 (24.0x Forward P/E, 14.4% operating margin), whereas OKUR carries 36.0/100 (SELL) at $2.70 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: LGND earns the overall head-to-head edge with a stronger Unified Composite Score (46.5/100 HOLD vs. OKUR 36.0/100 SELL) and 0.93β · 38% Vol risk profile, whereas OKUR leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 0 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: LGND trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 38.8); meanwhile OKUR is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 48.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About LGND vs OKUR
LGND NASDAQ Head-to-Head Winner
Ligand Pharmaceuticals Inc.
Pharmaceutical Preparations
$286.85
-0.03% 1D
Market Cap $5.7B
TTM Revenue $254M
Forward P/E 24.0x
Beta / 30D Vol 0.93β · 38% Vol
Unified Composite Score
46.5 / 100 HOLD
Tech 32.0 Fund 49.0 Flow 67.0 Mom 56.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 39
RSI-14: 38.8 · SMA20: $307.95 · SMA50: $302.35
OKUR NASDAQ
OnKure Therapeutics, Inc. Class A Common Stock
Pharmaceutical Preparations
$2.70
-2.17% 1D
Market Cap $113.7M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.96β · 100% Vol
Unified Composite Score
36.0 / 100 SELL
Tech 20.0 Fund 46.0 Flow 64.0 Mom 60.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -12.6%) with fading momentum, RSI 49
RSI-14: 48.7 · SMA20: $2.76 · SMA50: $2.67

6-Pillar Scorecard Institutional Category Breakdown (LGND 6 – 0 OKUR)

Columns: Metric · LGND · OKUR
1. Valuation Multiples LGND
Forward P/E 24.0x N/M
Trailing P/E 115.2x N/M
PEG Ratio 1.53x N/M
EV / Revenue 26.9x N/M
2. Growth & Scale LGND
Revenue Growth (YoY) -31.8% +0.0%
Earnings Growth (YoY) +825.0% +0.0%
TTM Revenue (USD) $254M N/A
Market Cap $5.7B $113.7M
3. Profitability & Quality LGND
Gross Margin 86.1% N/A
Operating Margin 14.4% 0.0%
Net Profit Margin 20.3% 0.0%
Return on Equity (ROE) 5.4% -55.2%
4. Balance Sheet & Cash Flow LGND
Cash Generation (TTM) $57M -$48M
Cash Flow Margin 22.6% N/A
Net Cash / Leverage $1.10B Net Debt (1.20x D/E) $151M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning LGND
Options Structure Phase CONSOLIDATION SURGE
Current IV / %ile 45.4% (9th %ile) 89.1% (100th %ile)
Put/Call OI Skew 0.19x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Neutral DISTRIBUTION · Distribution
6. R&D & Supply-Chain Moat LGND
OpEx & R&D Intensity 71.7% of Rev ($182M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: LGND (9) vs OKUR (1)
Institutional Metric LGND OKUR Criterion Row Edge
Market Capitalization
Scale
$5.7B $113.7M Larger Scale LGND
Trailing P/E Ratio
Valuation
115.2x N/M Lower Multiple LGND
Forward P/E Ratio
Valuation
24.0x N/M Lower Multiple LGND
Revenue Growth (YoY)
Growth
-31.8% +0.0% Higher Growth OKUR
Operating Margin (TTM)
Profitability
14.4% 0.0% Higher Margin LGND
Net Profit Margin
Profitability
20.3% 0.0% Higher Margin LGND
Return on Equity (ROE)
Capital Efficiency
5.4% -55.2% Higher ROE LGND
52-Week Range Position
Momentum
74% ($176–$327) 20% ($2–$5) Stronger Trend LGND
Beta / 30D Volatility
Risk Regime
0.93β · 38% Vol 0.96β · 100% Vol Lower Realized Risk LGND
Unified Institutional Score
Composite Signal
46.5 / 100 (HOLD) 36.0 / 100 (SELL) Higher Composite LGND
Trailing 12M Revenue (USD)
Operating Scale
$254M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
86.1% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.53x PEG · 26.9x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$57M ($1.10B Net Debt (1.20x D/E)) -$48M ($151M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon OKUR +11.46 pp
LGND: -6.81% · OKUR: +4.65%
3M Horizon LGND +32.97 pp
LGND: +2.38% · OKUR: -30.59%
6M Horizon LGND +60.95 pp
LGND: +25.08% · OKUR: -35.87%
1Y Horizon LGND +41.38 pp
LGND: +39.21% · OKUR: -2.17%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on LGND vs OKUR. Trailing 12-month operating profitability (LGND 14.4% vs OKUR 0.0%) and valuation multiples (LGND 24.0x vs OKUR N/M Forward P/E) are benchmarked directly in Pillar 4 below.

LGND ADR TTM Benchmark FX-Normalized USD
TTM Revenue$254M
Gross Margin86.1%
Op. Margin14.4%
ROE / Fwd P/E5.4% · 24.0x
OKUR ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-55.2% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
LGND CONSOLIDATION
102d in phase · OBV DISTRIBUTION
Current IV 45.4%
IV Percentile 9th %ile
Put/Call OI Skew 0.19x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact LGND Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
OKUR SURGE
8d in phase · OBV DISTRIBUTION
Current IV 89.1%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact OKUR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
LGND Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $5.7B market capitalization and 14.4% operating margin.
OpEx & R&D Reinvestment 71.7% of Rev ($182M)
90D Engineering Disclosures 0 Published
OKUR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $113.7M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ LGND vs OKUR Key Questions & Quantitative Answers

As of Nov 20, 2026, Ligand Pharmaceuticals Inc. (LGND) is the stronger overall head-to-head candidate over OnKure Therapeutics, Inc. (OKUR) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). LGND carries a Unified Composite Score of 46.5/100 (HOLD) at $286.85 (24.0x Forward P/E, 14.4% operating margin), whereas OKUR carries 36.0/100 (SELL) at $2.70 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: LGND earns the overall head-to-head edge with a stronger Unified Composite Score (46.5/100 HOLD vs. OKUR 36.0/100 SELL) and 0.93β · 38% Vol risk profile, whereas OKUR leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 0 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: LGND trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 38.8); meanwhile OKUR is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 48.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

LGND leads the Growth & Scale pillar: LGND posts -31.8% YoY revenue growth and +825.0% YoY earnings growth on $254M TTM revenue (86.1% gross margin, 14.4% operating margin), compared with OKUR at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, LGND generates $254M in USD-normalized revenue versus N/A for OKUR. In operating R&D and SG&A reinvestment, LGND deploys 71.7% of Rev ($182M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for OKUR.

LGND screens cheaper on headline valuation multiples. LGND trades at 24.0x Forward P/E, 115.2x Trailing P/E, 1.53x PEG, and 26.9x EV/Revenue (22.6% FCF margin), whereas OKUR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LGND (5.4% ROE) versus OKUR (-55.2% ROE) capital efficiency.

In options market volatility and institutional positioning, LGND carries 45.4% implied volatility (9th %ile, Compressed (<25th %ile)), a 0.19x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.93β · 38% Vol realized risk). By comparison, OKUR carries 89.1% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.96β · 100% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.